Table 2.
Combination indexe values of RO‐BIR2 and Ara‐C combination therapy in U‐937 AML cell line and AD448, AD330 primary AML cells (CI < 1, synergistic; CI > 1, antagonistic; CI = 1, additive)
| RO‐BIR2 (μm) | Ara‐C (nm) | Effect | CI |
|---|---|---|---|
| U‐937 | |||
| 2.0 | 1800.0 | 0.9 | 1.09764 |
| 2.0 | 600.0 | 0.87 | 0.45962 |
| 2.0 | 200.0 | 0.69 | 0.35757 |
| 2.0 | 66.67 | 0.42 | 0.28295 |
| 4.0 | 1800.0 | 0.9 | 1.09764 |
| 4.0 | 600.0 | 0.88 | 0.42837 |
| 4.0 | 200.0 | 0.76 | 0.27257 |
| 4.0 | 66.67 | 0.53 | 0.20119 |
| RO‐BIR2 (μm) | Ara‐C (nm) | Effect | CI |
|---|---|---|---|
| AD448 | |||
| 20 | 2800 | 0.97 | 0.20418 |
| 10 | 1400 | 0.94 | 0.21631 |
| 5 | 700 | 0.88 | 0.23914 |
| 2.5 | 350 | 0.76 | 0.34528 |
| 1.25 | 175 | 0.53 | 0.44894 |
| RO‐BIR2 (μm) | Ara‐C (nm) | Effect | CI |
|---|---|---|---|
| AD330 | |||
| 20 | 2800 | 0.779 | 0.29769 |
| 10 | 1400 | 0.702 | 0.29117 |
| 5 | 700 | 0.573 | 0.37161 |
| 2.5 | 350 | 0.421 | 0.51557 |
| 1.25 | 175 | 0.313 | 0.56162 |